ClinicalTrials.gg
CompletedNCT06603571Updated Sep 29, 2026

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

A Phase 2 interventional study of LY3841136 and Tirzepatide in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 52 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Updated Sep 29, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
367
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing eloralintide in Obesity — 13 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.

Enrollment
11th of 22
367 · median 315
Started
2024
with 3 others
Phase 2
5 of 22
2 open now
Registered
6th of 22
by date
Lead sponsor
22 of 22
Eli Lilly and Company

Among the 22 studies testing eloralintide in Obesity, this one is the 11th largest by enrollment, is one of 4 that started in 2024, is one of 5 in phase 2, and was the 6th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About eloralintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing eloralintide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

W8M-MC-LAA2

  • Have a (BMI) of ≥27 kilograms per square meter (kg/m²)
  • Have Type 2 Diabetes
  • Have a ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening

W8M-MC-CWMM:

  • Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)

Exclusion criteria

Exclusion Criteria:

W8M-MC-LAA2

  • Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
  • Have an on-going or history of bradyarrhythmia and/or sinus bradycardia
  • Have an elevated resting pulse rate (mean >100 beats per minute (bpm)) or reduced resting pulse rate (mean \<60 bpm) at screening
  • Have any of the following cardiovascular conditions within 6 months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure
  • Have renal impairment measured as estimated (eGFR) \<45 milliliters per minute (mL/min)/1.73 m2
  • Have a history of acute or chronic pancreatitis
  • Have fasting triglycerides >500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening
  • All concomitant medications should be at a stable dose for at least 3 months prior to screening

W8M-MC-CWMM

  • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
  • Have type 1 diabetes mellitus, latent diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
  • Have poorly controlled hypertension.
  • Have a history of symptomatic gallbladder disease within the past 2 years
  • Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
  • Have a lifetime history of suicide attempts.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
367 participants (actual)

Study arms

  • Experimental
    LY3841136 Dose 1

    Participants will receive LY3841136 subcutaneously (SC)

    Drug: LY3841136

  • Experimental
    LY3841136 Dose 2

    Participants will receive LY3841136 SC

    Drug: LY3841136

  • Experimental
    LY3841136 Dose 3

    Participants will receive LY3841136 SC

    Drug: LY3841136

  • Experimental
    LY3841136 Dose 1 + Tirzepatide Dose 1

    Participants will receive LY3841136 SC and Tirzepatide SC

    Drug: LY3841136 · Drug: Tirzepatide

  • Experimental
    LY3841136 Dose 2 + Tirzepatide Dose 1

    Participants will receive LY3841136 SC and Tirzepatide SC

    Drug: LY3841136 · Drug: Tirzepatide

  • Experimental
    LY3841136 Dose 2 + Tirzepatide Dose 2

    Participants will receive LY3841136 SC and Tirzepatide SC

    Drug: LY3841136 · Drug: Tirzepatide

  • Experimental
    LY3841136 Dose 3 + Tirzepatide Dose 3

    Participants will receive LY3841136 SC and Tirzepatide SC

    Drug: LY3841136 · Drug: Tirzepatide

  • Active comparator
    Tirzepatide Dose 3

    Participants will receive Tirzepatide SC

    Drug: Tirzepatide

  • Experimental
    LY3841136 Dose 2 + Tirzepatide Dose 3

    Participants will receive LY3841136 SC and Tirzepatide SC

    Drug: LY3841136 · Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants will receive placebo administered SC.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Change from Baseline in Body Weight

    Time frame: Baseline, Week 48

  2. Percentage of Participants Who Achieve ≥5% Body Weight Reduction

    Time frame: Week 48

  3. Percentage of Participants Who Achieve ≥10% Body Weight Reduction

    Time frame: Week 48

  4. Change from baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 48

  5. Pharmacokinetics (PK): Area Under the Curve (AUC) of LY3841136

    Time frame: Baseline, Week 48

  6. PK: Maximum Concentration (Cmax) of LY3841136

    Time frame: Baseline, Week 48

07

Study locations

52 sites
  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
    Chandler, Arizona 85225, United States
  • HOPE Research Institute
    Phoenix, Arizona 85032, United States
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson
    Tucson, Arizona 85712, United States
  • NorCal Medical Research, Inc
    Greenbrae, California 94904, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Northeast Research Institute (NERI)
    Fleming Island, Florida 32003, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Charter Research - Winter Park
    Orlando, Florida 32803, United States
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
  • Medical Research Partners
    Ammon, Idaho 83406, United States
  • Great Lakes Clinical Trials - Andersonville
    Chicago, Illinois 60640, United States
  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
  • NorthShore University Health System
    Skokie, Illinois 60077, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50266, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • Knownwell
    Needham, Massachusetts 02492, United States
  • Lucida Clinical Trials
    New Bedford, Massachusetts 02740, United States
  • Headlands Research - Detroit
    Southfield, Michigan 48034, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Clinvest Headlands Llc
    Springfield, Missouri 65807, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
  • Velocity Clinical Research, Syracuse
    East Syracuse, New York 13057, United States
  • North Suffolk Neurology
    Port Jefferson Station, New York 11776, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Medication Management
    Greensboro, North Carolina 27405, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
  • Lucas Research, Inc.
    New Bern, North Carolina 28562, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
  • IMA Clinical Research Austin
    Austin, Texas 78745, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75251, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Tekton Research - Fredericksburg Road
    San Antonio, Texas 78229, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • Texas Valley Clinical Research
    Weslaco, Texas 78596, United States
  • Spectrum Medical, Inc.
    Danville, Virginia 24541, United States
  • Central Washington Health Services Association d/b/a Confluence Health
    Wenatchee, Washington 98801, United States
  • Centro de Investigaciones Metabólicas (CINME)
    Buenos Aires, C1056ABI, Argentina
  • Centro Médico Viamonte
    Buenos Aires, C1120AAC, Argentina
  • Consultorio de Investigación Clínica EMO SRL
    Buenos Aires, C1405BUB, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, C1425AGC, Argentina
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jul 2026, 21 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 21 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Sep 20, 2024
Primary completionActual
Jul 1, 2026
CompletionActual
Sep 14, 2026was Aug 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 29, 2026
Study completion
Aug 2026→Sep 14, 2026 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Active, not recruiting→Completed
    Study completion Aug 2026→Sep 14, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06603571
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 20, 2024
Primary completion
Jul 1, 2026
Completion
Sep 14, 2026
Last update
Sep 29, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eloralintide

Start the discussion